Neurim, Flynn discover that time is not on their side

In the third chapter of Neurim and Flynn’s dispute with generic companies, handed down on April 23, Mr Justice Mellor refused the claimants’ application for an interim injunction against generic giant, Teva, on the basis that Teva would not be adequately compensated by damages if its melatonin product was taken off the market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

English appeals court refuses Neurim injunction for insomnia drug

26 June 2020 The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Big Pharma

English High Court denies Mylan a stay in Neurim litigation

2 November 2021 Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

Big Pharma

English High Court rejects second injunction bid over melatonin medicine

30 June 2022 Justice Mellor was unconvinced by arguments that Teva could have cleared the way.

More on this story

Big Pharma

English appeals court refuses Neurim injunction for insomnia drug

26 June 2020 The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Big Pharma

English High Court denies Mylan a stay in Neurim litigation

2 November 2021 Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

Big Pharma

English High Court rejects second injunction bid over melatonin medicine

30 June 2022 Justice Mellor was unconvinced by arguments that Teva could have cleared the way.

More on this story

Big Pharma

English appeals court refuses Neurim injunction for insomnia drug

26 June 2020 The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Big Pharma

English High Court denies Mylan a stay in Neurim litigation

2 November 2021 Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

Big Pharma

English High Court rejects second injunction bid over melatonin medicine

30 June 2022 Justice Mellor was unconvinced by arguments that Teva could have cleared the way.